Myriad Genetics Inc (MYGN) Stock Price, Quote & News

Company Profile

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastati...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 801 584 3600

Fax: 801 584 3640

Website: www.myriad.com

Address:

322 North 2200 West, Salt Lake City, United States

PeakedSeller Sep. 11 at 9:57 PM

$MYGN closed $7.68—breakout held. Next gates $7.95–$8.20 then $8.8–$9.2. Strategy & margins intact (guide up, ~70% GM, EBITDA +). $9–10 into Q3 very much alive. 📈

0 · Reply

PeakedSeller Sep. 11 at 6:56 PM

$MYGN clear breakout🙌🏻

0 · Reply

ZacksResearch Sep. 8 at 12:19 PM

$MYGN — After a 75.5% plunge over the past year, is there a turnaround in sight? 🔍 🧬 New Phase 2 trial shows promise for Myriad Genetics' Precise MRD in ccRCC. The trial indicated that patients with low ctDNA levels might delay systemic treatments, potentially sparing them from side effects. 📉 Despite recent news, shares dropped 2.7%, but a strong Oncology expansion strategy could shift market sentiment. Discover what could drive MYGN's recovery 👉 https://www.zacks.com/stock/news/2747817/mygn-stock-might-gain-on-the-lancet-study-backing-precise-mrd?cid=sm-stocktwits-2-2747817-body-11229&ADID=SYND_STOCKTWITS_TWEET_2_2747817_BODY_11229

0 · Reply

ZacksResearch Sep. 8 at 11:19 AM

$MYGN could be setting up for a breakout 🚀 The Lancet just backed its Precise MRD with strong ctDNA detection results in oligometastatic ccRCC — a big validation for its oncology growth strategy. Full breakdown here 👉 https://www.zacks.com/stock/news/2747817/mygn-stock-might-gain-on-the-lancet-study-backing-precise-mrd?cid=sm-stocktwits-2-2747817-teaser-11228&ADID=SYND_STOCKTWITS_TWEET_2_2747817_TEASER_11228

0 · Reply

PeakedSeller Sep. 5 at 7:08 PM

$MYGN New meta-analysis (JCP) shows GeneSight improves remission +41% and response +30% vs TAU (n=3,532). Co confirms it’ll submit to payers. With price above $6.9, eyes on $7.5–8.2 next; clean Q3 keeps $9–10 in play. 📈🔬

0 · Reply

PeakedSeller Sep. 5 at 7:02 PM

$MYGN https://investor.myriad.com/news-releases/news-release-detail/26641/

2 · Reply

PeakedSeller Sep. 5 at 7:01 PM

$MYGN https://investor.myriad.com/news-releases/news-release-detail/26656/

0 · Reply

ZacksResearch Sep. 5 at 4:59 PM

$MYGN breakthrough in depression treatment — stock momentum next? 🚀 GeneSight just proved superior to treatment-as-usual in major depression, a result that could fuel wider adoption and investor interest. Full breakdown here 👉 https://www.zacks.com/stock/news/2747645/mygns-genesight-test-proven-superior-to-tau-stock-to-gain?cid=sm-stocktwits-2-2747645-teaser-11205&ADID=SYND_STOCKTWITS_TWEET_2_2747645_TEASER_11205

0 · Reply

ZacksResearch Sep. 5 at 3:59 PM

$MYGN making waves with its GeneSight Psychotropic test! 🌊 📊 Meta-analysis shows MDD patients in the GeneSight arm are 41% more likely to achieve remission and 30% more likely to achieve a response compared to TAU. 📈 Long-term EPS growth rate of 33.1%, compared with industry’s 21.1%. See what this means for Myriad Genetics' stock potential 👉 https://www.zacks.com/stock/news/2747645/mygns-genesight-test-proven-superior-to-tau-stock-to-gain?cid=sm-stocktwits-2-2747645-body-11172&ADID=SYND_STOCKTWITS_TWEET_2_2747645_BODY_11172

0 · Reply

v92 Sep. 5 at 11:32 AM

$MYGN what a gem!!!!

0 · Reply

Myriad Genetics, Inc. (MYGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 7:00 PM EDT - 9 days ago

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

Sep 3, 2025, 4:30 PM EDT - 11 days ago

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

Aug 27, 2025, 4:05 PM EDT - 18 days ago

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Aug 18, 2025, 8:30 AM EDT - 27 days ago

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

Aug 13, 2025, 8:00 AM EDT - 4 weeks ago

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

Aug 6, 2025, 5:51 PM EDT - 5 weeks ago

Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth

Aug 6, 2025, 4:14 AM EDT - 5 weeks ago

Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 5 weeks ago

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

Jun 3, 2025, 9:00 AM EDT - 3 months ago

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

May 27, 2025, 4:05 PM EDT - 3 months ago

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

May 27, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation

May 26, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect

May 25, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out

May 23, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation

May 22, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation

May 21, 2025, 10:00 AM EDT - 4 months ago

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 20, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Investors to Connect

May 19, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Stockholders to Inquire about Securities Investigation

May 16, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Investors to Reach Out

May 15, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out

May 14, 2025, 4:45 PM EDT - 4 months ago

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

May 14, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Connect

May 13, 2025, 10:00 AM EDT - 4 months ago

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 12, 2025, 7:15 PM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Stockholders to Learn More About the Investigation

May 6, 2025, 11:35 PM EDT - 4 months ago

Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 4 months ago

Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

May 2, 2025, 12:58 AM EDT - 4 months ago

Myriad Genetics: Significantly Undervalued With Profitability In Sight

Apr 30, 2025, 8:00 AM EDT - 4 months ago

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

Apr 25, 2025, 4:05 PM EDT - 5 months ago

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

Apr 21, 2025, 4:05 PM EDT - 5 months ago

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

Apr 8, 2025, 4:15 PM EDT - 5 months ago

Myriad Genetics Announces Inducement Awards

Apr 7, 2025, 8:00 AM EDT - 5 months ago

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

Feb 25, 2025, 2:22 PM EST - 7 months ago

Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO

UNH

Feb 24, 2025, 8:03 PM EST - 7 months ago

Myriad Genetics, Inc. (MYGN) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 4:05 PM EST - 7 months ago

Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth

Feb 24, 2025, 8:30 AM EST - 7 months ago

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

Feb 19, 2025, 8:30 AM EST - 7 months ago

Myriad Genetics Included in Forbes America's Best Employers 2025 List

Feb 6, 2025, 8:30 AM EST - 7 months ago

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

PeakedSeller Sep. 11 at 9:57 PM

$MYGN closed $7.68—breakout held. Next gates $7.95–$8.20 then $8.8–$9.2. Strategy & margins intact (guide up, ~70% GM, EBITDA +). $9–10 into Q3 very much alive. 📈

0 · Reply

PeakedSeller Sep. 11 at 6:56 PM

$MYGN clear breakout🙌🏻

0 · Reply

ZacksResearch Sep. 8 at 12:19 PM

0 · Reply

ZacksResearch Sep. 8 at 11:19 AM

0 · Reply

PeakedSeller Sep. 5 at 7:08 PM

0 · Reply

PeakedSeller Sep. 5 at 7:02 PM

$MYGN https://investor.myriad.com/news-releases/news-release-detail/26641/

2 · Reply

PeakedSeller Sep. 5 at 7:01 PM

$MYGN https://investor.myriad.com/news-releases/news-release-detail/26656/

0 · Reply

ZacksResearch Sep. 5 at 4:59 PM

0 · Reply

ZacksResearch Sep. 5 at 3:59 PM

0 · Reply

v92 Sep. 5 at 11:32 AM

$MYGN what a gem!!!!

0 · Reply

v92 Sep. 2 at 7:41 PM

$MYGN So someone knows something. This is a prime M&A target!!!

1 · Reply

PeakedSeller Sep. 2 at 7:19 PM

$MYGN incredible movement today breaking through the 6.9 resistance. A close above 6.95 confirms a breakout! We are looking strong!

0 · Reply

PeakedSeller Aug. 28 at 4:32 PM

$MYGN

0 · Reply

StockConsultant Aug. 28 at 2:15 PM

$MYGN Myriad Genetics stock, upside gap breakout at https://stockconsultant.com/?MYGN

0 · Reply

HeavyDtwitter Aug. 27 at 11:23 PM

$MYGN $THAR

0 · Reply

HeavyDtwitter Aug. 25 at 11:04 AM

$MYGN

1 · Reply

PeakedSeller Aug. 22 at 2:44 PM

$MYGN told you rate cuts were coming…

1 · Reply

PeakedSeller Aug. 21 at 8:05 PM

$MYGN that 10% recovery from support yesterday is a great sign moving forward

0 · Reply

PeakedSeller Aug. 21 at 3:34 AM

$MYGN shook out weak hands and closed green at support. Next: reclaim $6.3–6.5, then $6.9 opens $7.5–8.2. Clean Q3 keeps $9–10 in play by year end. 📈 Guidance was already reaffirmed this week when new CFO took over. Great time to be a Myriad investor🙌🏻💰

0 · Reply

Elo478 Aug. 20 at 8:32 PM

$MYGN bought back in at 5.28 gucci gang

0 · Reply

PeakedSeller Aug. 20 at 3:37 PM

$MYGN just loaded more calls for this. Awesome pullback opportunity

0 · Reply

PeakedSeller Aug. 19 at 8:46 PM

$MYGN

1 · Reply

Market Cap	673.65M
Revenue (ttm)	837.60M
Net Income (ttm)	-127.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-15.20%
Debt to Equity Ratio	0.15

Volume	2,000,400
Avg Vol	1,785,324
Day's Range	N/A - N/A
Shares Out	93.05M
Stochastic %K	62%
Beta	1.93
Analysts	Sell
Price Target	$7.42